Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
February 5, 2020
Presentation
Key Opinion Leader Symposium: CG-806 for AML
Key Opinion Leader Symposium: CG-806 for AML:
View Presentation
December 7, 2019
Presentation
Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253
Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253:
View Presentation
December 12, 2018
Presentation
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers:
View Presentation
Previous
1
2
3